Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Peabody

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
Journal of Nanobiotechnology|August 2, 2003
A Viral Platform for Chemical Modification and Multivalent DisplayDavid S Peabody
Nucleic Acids Research|October 5, 2002
RNA recognition site of PP7 coat proteinFrancis Lim, David S Peabody
Viruses|January 16, 2020
Factors That Govern the Induction of Long-Lived Antibody ResponsesBryce Chackerian, David S Peabody
Journal of Nanobiotechnology|November 28, 2007
Stability and assembly in vitro of bacteriophage PP7 virus-like particlesJerri C Caldeira, David S Peabody
Journal of Nanobiotechnology|May 26, 2011
Thermal stability of RNA phage virus-like particles displaying foreign peptidesJerri C Caldeira, David S Peabody
Archives of Biochemistry and Biophysics|August 15, 2002
Recognition of diverse RNAs by a single protein structural frameworkMarc Spingola, Francis Lim, David S Peabody
Current Opinion in Virology|April 2, 2015
Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platformJohn P O'Rourke, David S Peabody, Bryce Chackerian
Current Opinion in Virology|April 5, 2016
Engineering virus-like particles as vaccine platformsKathryn M Frietze, David S Peabody, Bryce Chackerian
Vaccine|June 30, 2006
Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responsesBryce Chackerian, Marisa Rangel, Zoe Hunter, et al.
Vaccine|August 13, 2013
A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvantsEbenezer Tumban, Julianne Peabody, David S Peabody, et al.
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Journal of Nanobiotechnology|August 2, 2003
A Viral Platform for Chemical Modification and Multivalent DisplayDavid S Peabody
Nucleic Acids Research|October 5, 2002
RNA recognition site of PP7 coat proteinFrancis Lim, David S Peabody
Viruses|January 16, 2020
Factors That Govern the Induction of Long-Lived Antibody ResponsesBryce Chackerian, David S Peabody
Journal of Nanobiotechnology|November 28, 2007
Stability and assembly in vitro of bacteriophage PP7 virus-like particlesJerri C Caldeira, David S Peabody
Journal of Nanobiotechnology|May 26, 2011
Thermal stability of RNA phage virus-like particles displaying foreign peptidesJerri C Caldeira, David S Peabody
Archives of Biochemistry and Biophysics|August 15, 2002
Recognition of diverse RNAs by a single protein structural frameworkMarc Spingola, Francis Lim, David S Peabody
Current Opinion in Virology|April 2, 2015
Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platformJohn P O'Rourke, David S Peabody, Bryce Chackerian
Current Opinion in Virology|April 5, 2016
Engineering virus-like particles as vaccine platformsKathryn M Frietze, David S Peabody, Bryce Chackerian
Vaccine|June 30, 2006
Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responsesBryce Chackerian, Marisa Rangel, Zoe Hunter, et al.
Vaccine|August 13, 2013
A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvantsEbenezer Tumban, Julianne Peabody, David S Peabody, et al.
Pageof 5